Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233960 · ClinicalTrials.gov registry record · Phase 3
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
NCT01233960 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 73 participants.
The verdict
NCT01233960, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
Study Summary
To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
Interventions
- DRUG Prochymal®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-11-29 |
| Est. Completion | 2014-09-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233960
The ClinicalTrials.gov registry entry for NCT01233960 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prochymal® is the first listed.
NCT01233960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233960 about?
NCT01233960 is a clinical study titled "Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease". To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
What is the current status of trial NCT01233960?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2010-11-29. Estimated completion is 2014-09-15.
What interventions are being tested in trial NCT01233960?
The interventions under investigation include: Prochymal® (DRUG).
Who is sponsoring clinical trial NCT01233960?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.